In a phase II, open label, randomized, multi-center trial, 153 patients with advanced, metastatic RCC who had received a VEGF targeted therapy were treated with lenvatinib, everolimus, or lenvatinib plus everolimus. This evidence concerns the gene VEGFA and renal cell carcinoma.